Credit Suisse Starts Galapagos NV (GLPG) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Nomura Securities Starts Galapagos NV (GLPG) at Buy
June 8, 2015 9:31 AM EDTNomura Securities initiates coverage on Galapagos NV (NASDAQ: GLPG) with a Buy rating and a price target of $73.00.
Analyst M. Ian Somaiya commented, "Our Buy rating is supported by the blockbuster opportunity for the companys lead oral JAK1 inhibitor, filgotinib, for the... More
Cowen Starts Galapagos NV (GLPG) at Outperform
June 8, 2015 6:41 AM EDTCowen initiates coverage on Galapagos NV (NASDAQ: GLPG) with a Outperform rating.
Analyst Phil Nadeau commented, "Galapagos has advanced a broad and deep pipeline into clinical development, with four candidates currently in clinical testing. Filgotinib has produced impressive results in Ph. IIb trials in... More
